Page 2 - Dr Reddys News Today

The sale happened in the ordinary course of transaction, according to the insurer.

Private equity firm Bain Capital has approached Indian pharmaceutical company Dr Reddys Laboratories (DRL) to explore a joint bid for the promoters of Cipla, the Hamied family. DRL is evaluating the opportunity and countering an offer from Torrent Pharma, another Indian investor. If DRL decides to participate, the combined entity would become the leading Indian-origin pharma major at home and in the US and emerging markets.

Dr. Reddys Laboratories, incorporated in the year 1984, is a Large Cap company (having a market cap of Rs 97945.46 Crore) operating in Pharmaceuticals sector.

India News: HYDERABAD: Pharma major Reddy’s Laboratories Ltd on Thursday announced its foray into the Indian child nutrition space with the rollout of its immunit.

The Hyderabad-based companys consolidated profit rose to Rs 959 crore in the three months ended 31 March, compared with Rs 875 crore a year earlier, , dr reddys

Dr. Reddy’s Laboratories Limited announced that the Nomination, Governance and Compensation Committee of the Board of Directors of the company has approved the allotment of 1,022 equity shares of Rs 5 each of the company, fully paid up, on March 20, 2023, via an exchange filing. The issue is to employees pursuant to exercise of their Stock Options, as per the following details:

Under the agreement, Eris Lifesciences will be assigned the trademark of these brands by Dr. Reddy’s for a consideration of Rs. 275 cr. As per IQVIA MAT December 2022, the divested portfolio saw sales of Rs. 60 cr in India.

Dr. Reddy’s Laboratories Limited informed that the the Nomination, Governance and Compensation Committee of the Board of Directors of the Company has approved the allotment of 1,342 equity shares of Rs 5 each, fully paid up, on February 16, 2023, to employees pursuant to exercise of their stock options, via an exchange filing. The equity shares of Rs 5 each, pursuant to Dr. Reddy's ESOPs.

Dr Reddy's will also pay more than $12 million to the purchaser for site-related expenses.

Under its sustainability goals for the next decade, Dr Reddy's said it is making its ''products accessible and affordable for patients'' and ''25 per cent of new launches to be first to market by 2027''.